We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

63 hedge funds and large institutions have $515M invested in 4D Molecular Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 11

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

29% more capital invested

Capital invested by funds: $400M → $515M (+$115M)

13% more funds holding

Funds holding: 56 → 63 (+7)

8.89% more ownership

Funds ownership: 62.1% → 71% (+8.9%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
63
Holders Change
+7
Holders Change %
+12.5%
% of All Funds
1.1%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
11
Increased
32
Reduced
11
Closed
4
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$20.2M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13.6M
3
CC
Centiva Capital
New York
+$10.2M
4
JP Morgan Chase
JP Morgan Chase
New York
+$6.18M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.98M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$5.61M
2
Morgan Stanley
Morgan Stanley
New York
-$1.78M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$901K
4
ACH
ArrowMark Colorado Holdings
Colorado
-$754K
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$531K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
51
Osaic Holdings
Arizona
$158K – – –
Legal & General Group
52
Legal & General Group
United Kingdom
$149K +$134K +4,691 +576%
TRCT
53
Tower Research Capital (TRC)
New York
$84K +$60.7K +2,129 +219%
Citigroup
54
Citigroup
New York
$76K +$34.7K +1,218 +77%
Royal Bank of Canada
55
Royal Bank of Canada
Ontario, Canada
$63K +$47.6K +1,669 +247%
Macquarie Group
56
Macquarie Group
Australia
$62K +$65.6K +2,300 New
AIP
57
Ameritas Investment Partners
Nebraska
$43K +$27.7K +973 +154%
UBS Group
58
UBS Group
Switzerland
$34K +$35.8K +1,256 New
Rockefeller Capital Management
59
Rockefeller Capital Management
New York
$28K -$3.71K -130 -11%
US Bancorp
60
US Bancorp
Minnesota
$9K +$8.5K +298 +1,490%
S
61
SignatureFD
Georgia
$5K +$2.68K +94 +109%
EWA
62
Evolution Wealth Advisors
Florida
$4K -$6.16K -216 -60%
NFSG
63
Newbridge Financial Services Group
Florida
$1K – – –
Jacobs Levy Equity Management
64
Jacobs Levy Equity Management
New Jersey
– -$901K -37,417 Closed
Walleye Capital
65
Walleye Capital
New York
– -$294 -12,205 Closed
VIA
66
Vident Investment Advisory
Georgia
– -$205K -8,521 Closed
Federated Hermes
67
Federated Hermes
Pennsylvania
– -$101K -4,200 Closed
1 2
3

FDMT Hedge Fund Activity: Q3 2021 in Review

63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2021, worth a combined $515M — up 29% from $400M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new FDMT positions and 4 closed out — a net gain of 7 holders — while 32 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $20.2M. The largest seller was Millennium Management, cutting an estimated $5.61M.

  • 63 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2021, up from 56 in Q2 2021.
  • Funds reported $515M of 4D Molecular Therapeutics stock for Q3 2021, up 29% quarter-over-quarter.
  • 11 funds opened new 4D Molecular Therapeutics positions in Q3 2021 and 4 closed out, a net change of +7 holders.
  • The largest 4D Molecular Therapeutics buyer in Q3 2021 was BlackRock, an estimated $20.2M added.
  • The largest 4D Molecular Therapeutics seller in Q3 2021 was Millennium Management, an estimated $5.61M sold.

Based on aggregated 13F filings for Q3 2021.